Nelotanserin is an investigational drug candidate that has the potential to be a best-in-class, once-daily, orally-administered, potent and highly selective inverse agonist of the 5HT2A receptor. The 5HT2A receptor has been linked to neuropsychiatric disturbances including visual hallucinations – a common occurrence in people living with Lewy body dementia. Axovant intends to develop nelotanserin to address multiple aspects of Lewy body dementia.
We believe that nelotanserin has a number of favorable properties as a product candidate for dementia:
Highly potent and highly selective at the 5HT2A receptor
Minimal or no activity at the 5HT2C, D2 or H1 receptors
Well tolerated in the seven clinical studies completed to date with nearly 800 human subjects exposed to the drug candidate
No evidence of QTc prolongation
Oral, once-daily administration
Nelotanserin is an investigational new drug candidate and is not approved for any indication in any markets.